Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648–1671.

    CAS  Article  Google Scholar 

  2. 2

    Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044–1054.

    CAS  Article  Google Scholar 

  3. 3

    Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016; 34: 2333–2340.

    CAS  Article  Google Scholar 

  4. 4

    Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol 2014; 89: 732–742.

    CAS  Article  Google Scholar 

  5. 5

    Cortes JE, Kim D-W, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 2014; 124: 3135.

    Google Scholar 

  6. 6

    Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014; 89: 947–953.

    CAS  Article  Google Scholar 

  7. 7

    Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128–2137.

    CAS  Article  Google Scholar 

  8. 8

    Seferian A, Chaumais MC, Savale L, Günther S, Tubert-Bitter P, Humbert M et al. Drugs induced pulmonary arterial hypertension. Presse Med 2013; 42 (9 Pt 2): e303–e310.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Nathalie Ross, Science and Medical Writer, funded by Novartis Pharmaceuticals for contributing to the writing and editing of this Correspondence. Novartis had no influence on the content of this document.

Author information

Affiliations

Authors

Corresponding author

Correspondence to C Constance.

Ethics declarations

Competing interests

Dr Christian Constance has received honorarium and support for clinical trials from Astra, Bayer, Boehringer Ingelheim, Novartis and Pfizer. Dr David Langleben has received honoraria and support for clinical trials from Actelio, Bayer, Eiger Biophamaceuticals, Ikaria, Northern Therapeutics, Novartis and United Therapeutics. He has served on advisory boards for Actelion, Bayer, Ikaria, Northern Therapeutics, Novartis, UCB Celltech and United Therapeutics. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Constance, C., Trudeau, L., Jolicoeur, E. et al. Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 31, 771–772 (2017). https://doi.org/10.1038/leu.2016.336

Download citation

Further reading